Lantheus (NASDAQ:LNTH) Stock Crosses Above Fifty Day Moving Average – Here’s Why

Lantheus Holdings, Inc. (NASDAQ:LNTH)’s stock price crossed above its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of $100.25 and traded as high as $100.50. Lantheus shares last traded at $100.32, with a volume of 771,628 shares changing hands.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Truist Financial cut shares of Lantheus from a “buy” rating to a “hold” rating and cut their target price for the stock from $125.00 to $102.50 in a report on Monday, August 3rd. Brookline Capital Markets lowered Lantheus from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 28th. Weiss Ratings lowered Lantheus from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, October 15th. William Blair set a $102.50 price target on Lantheus in a research report on Monday, August 3rd. Finally, CJS Securities lowered Lantheus from a “market outperform” rating to a “market perform” rating in a research report on Tuesday, August 4th. Three research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $107.44.

Lantheus Stock Performance

The company has a current ratio of 3.06, a quick ratio of 2.89 and a debt-to-equity ratio of 0.43. The company’s 50-day moving average is $100.26 and its two-hundred day moving average is $91.17. The stock has a market capitalization of $6.56 billion, a P/E ratio of 24.27 and a beta of -0.06.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 EPS for the quarter, topping the consensus estimate of $1.30 by $0.25. The firm had revenue of $388.18 million during the quarter, compared to analysts’ expectations of $363.23 million. Lantheus had a net margin of 17.69% and a return on equity of 28.10%. Lantheus’s quarterly revenue was up 2.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.57 EPS. As a group, sell-side analysts anticipate that Lantheus Holdings, Inc. will post 4.54 EPS for the current fiscal year.

Institutional Trading of Lantheus

Hedge funds have recently added to or reduced their stakes in the business. Oregon Public Employees Retirement Fund grew its stake in shares of Lantheus by 0.7% in the third quarter. Oregon Public Employees Retirement Fund now owns 13,559 shares of the medical equipment provider’s stock worth $1,350,000 after acquiring an additional 100 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of Lantheus by 3.3% during the 3rd quarter. GAMMA Investing LLC now owns 3,457 shares of the medical equipment provider’s stock worth $344,000 after purchasing an additional 109 shares during the period. ABS Investment Management LLC bought a new position in shares of Lantheus during the 2nd quarter worth about $232,974,000. Versant Capital Management Inc raised its position in shares of Lantheus by 33.0% during the second quarter. Versant Capital Management Inc now owns 588 shares of the medical equipment provider’s stock valued at $65,000 after buying an additional 146 shares during the last quarter. Finally, Abel Hall LLC raised its position in shares of Lantheus by 4.6% during the first quarter. Abel Hall LLC now owns 3,915 shares of the medical equipment provider’s stock valued at $297,000 after buying an additional 172 shares during the last quarter. Institutional investors own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc is a diagnostic imaging and radiopharmaceutical company that develops, manufactures and commercializes products used to help physicians detect, characterize and monitor disease. Its portfolio supports imaging in areas including oncology, cardiology and other medical specialties.

The company’s products include DEFINITY, an ultrasound-enhancing agent used in cardiac and other ultrasound examinations, and PYLARIFY, a prostate-specific membrane antigen (PSMA) PET imaging agent used to help identify and manage prostate cancer.